Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day) by Lanteri-Minet, M. et al.
ORIGINAL
Cardiac safety in cluster headache patients using the very high
dose of verapamil (‡720 mg/day)
M. Lanteri-Minet • F. Silhol • V. Piano •
A. Donnet
Received: 3 September 2010/Accepted: 29 December 2010/Published online: 22 January 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Use of high doses of verapamil in preventive
treatment of cluster headache (CH) is limited by cardiac
toxicity. We systematically assess the cardiac safety of the
very high dose of verapamil (verapamil VHD) in CH
patients. Our work was a study performed in two French
headache centers (Marseilles–Nice) from 12/2005 to
12/2008. CH patients treated with verapamil VHD
(C720 mg) were considered with a systematic electrocar-
diogram (EKG) monitoring. Among 200 CH patients, 29
(14.8%) used verapamil VHD (877 ± 227 mg/day). Inci-
dence of EKG changes was 38% (11/29). Seven (24%)
patients presented bradycardia considered as nonserious
adverse event (NSAE) and four (14%) patients presented
arrhythmia (heart block) considered as serious adverse event
(SAE). Patients with EKG changes (1,003 ± 295 mg/day)
were taking higher doses than those without EKG changes
(800 ± 143 mg/day), but doses were similar in patients
with SAE (990 ± 316 mg/day) and those with NSAE
(1,011 ± 309 mg/day). Around three-quarters (8/11) of
patients presented a delayed-onset cardiac adverse event
(delay C2 years). Our work conﬁrms the need for sys-
tematic EKG monitoring in CH patients treated with
verapamil. Such cardiac safety assessment must be con-
tinued even for patients using VHD without any adverse
event for a long time.
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Introduction
According to quality criteria developed by the American
Academy of Neurology [1], verapamil received a grade C
rating in a recent meta-analysis of trials of pharmacotherapy
for cluster headache (CH) [2]. In spite of this low evidence
level, verapamil is generally considered to be the mainstay
of CH preventive therapy as in the European guidelines [3].
The starting daily dose of verapamil in CH should be the
360 mg effective in two randomized clinical trials [4, 5].
The daily dose could be increased up to 720 mg and some
CH patients may even need unusual very high daily dose
from 720 to 1,200 mg [6]. Considering such a clinical
practice, the dose of verapamil used for CH is approxi-
mately twice the dose required by cardiovascular diseases
[7]. This difference could be explained by the fact that the
cardiovascular effects are related to blood level, whereas
the preventive CH effect takes place across the blood–brain
barrier where the efﬂux transporter P-glycoprotein restricts
net brain uptake of verapamil by immediately transporting
it out of the brain [8]. Considering the use of high doses, the
cardiac safety of verapamil therapy was speciﬁcally studied
in one series that included 108 CH patients treated
by verapamil with systematic electrocardiogram (EKG)
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240 mg/day and then increased until the CH was sup-
pressed, or to a maximum daily dose of 960 mg (mean daily
dose 584 ± 257 mg) and incidence of arrhythmia was 19%
and bradycardia 36% [9]. We developed a similar approach
to assess the cardiac safety of verapamil therapy in CH with
a focus on very high daily dose equal or higher than
720 mg/day.
Methods
The notes were assessed for patients with episodic CH or
chronic CH attending two headache specialty centers
(Marseilles and Nice) belonging to the French Observatory
of Migraine and Headaches [10] from December 2005 to
December 2008. Patients had a diagnosis of CH according
to the criteria of the second edition of the International
Classiﬁcation of Headache Disorders [11]. When the
verapamil was used, the starting dose was 360 mg with an
increase by 120 mg every 2 weeks with a check EKG, until
the CH was suppressed or adverse events intervened.
Ordinary release formulation or controlled release formu-
lation were both used.
Study considered CH patients using verapamil with a
very high daily dose deﬁned as C720 mg. The following
data were collected for each patient: sex, age, tobacco use
and cardiovascular history, diagnosis (episodic or chronic
CH), duration of verapamil use, very high dose of verap-
amil achieved, duration of use of such a very high dose
of verapamil, concomitant medications, clinical adverse
events related to verapamil (constipation, lethargy, hypo-
tension, lower edema, dyspnea, impotence, gingival
hyperplasia). EKG assessment before verapamil introduc-
tion was compared with EKG assessment done at the very
high dose of verapamil achieved.
Results
Patients
Among 200 CH identiﬁed seen during the study period,
29 (14.8%) used verapamil with a daily dose C720 mg.
Very high verapamil dose CH patients were 28 men and
1 woman with a mean age 43.2 ± 10 years (range
21–55 years). Twenty one were present smokers, six were
past smokers and two had never smoked. Three had a high
blood pressure and one a coronary heart disease. Nine
suffered of episodic CH and 20 of chronic CH. Mean
duration of verapamil therapy was 46 ± 36 months and
mean duration of very high dose use was 36 ± 32 months.
Mean very high dose of verapamil was 877 ± 227 mg/day
(720 mg: 16; 840 mg: 2; 960 mg: 7; 1,200 mg: 1;
1,440 mg: 3). Concomitant treatments for CH (acute and
prophylactic) are presented in Table 1.
EKG changes
EKG changes concerned 11 (38%) patients: bradycardia
(heart rate\60 bpm) in 7 patients, ﬁrst-degree heart block
(PR interval [0.2 s) in 2 patients, second-degree heart
block in 1 patient and third degree heart block in 1 patient.
Patients with EKG changes used a mean verapamil daily
dose of 1,003 ± 295 mg, whereas patients without EKG
changes used a mean verapamil dose of 800 ± 143 mg.
EKG changes have been considered as cardiac serious
adverse event (SAE) in the four (14%) patients with heart
block inducing verapamil discontinuation in two patients
and a dose reduction in one patient. EKG changes have
been considered as cardiac nonserious adverse event
(NSAE) in seven (24%) patients with bradycardia, but
verapamil dose was decreased in one patient.
Cardiac SAE concerned 4 men with mean age
40.2 ± 14.5 years (range 21–52 years) and using a mean
very high verapamil daily dose of 990 ± 315 mg. One
patient had a high blood pressure history and regarding
tobacco use, two were present smokers, one was past
smoker and one patient had never smoked. Cardiac SAE
concerned patients using verapamil without concomitant
medications expect sumatriptan or zolmitriptan as acute
treatment. Cardiac SAE were delayed onset in three
patients (72, 71 and 24 months after the very high dose was
achieved). Cardiac SAE were asymptomatic in two patients
and symptomatic in two patients with lethargy, and dysp-
nea for one patient and lethargy for the other.
Cardiac NSAE concerned seven men with mean age
40.7 ± 10 years (range 28–52 years) and using a mean
very high verapamil daily dose of 1,011 ± 309 mg. No
patient had cardiovascular history and regarding tobacco
use, six were present smokers and one had never smoked.
Cardiac NSAE concerned one patient without any con-
comitant treatment, three patients without concomitant
treatment except acute treatment (sumatriptan and oxygen)
and three patients with prophylactic concomitant treatment
(topiramate and/or indomethacin). Cardiac NSAE was
delayed onset in ﬁve patients (60, 36, 27, 24 and 24 months
after the very high dose was achieved). Cardiac NSAE
were asympomatic in four patients and associated lethargy
in the three other patients.
Discussion
Considering the frequent use of high daily doses, cardiac
safety assessment with systematic EKG monitoring is
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123essential in the management of CH patients treated by
verapamil [7]. This is all the more essential as the very high
daily dose (C720 mg) is used. The use of the very high
daily dose is not infrequent and our study showed that it
corresponds to 14.8% of CH patients managed in two
centers representative of French headache tertiary centers.
In this group patients treated with the very high daily dose
of verapamil (877 ± 227 mg), systematic EKG monitoring
demonstrated that incidence of cardiac adverse events is
38%, with more than one-third of cases, the occurrence of
an adverse event was considered as serious. Cardiac SAE
were arrhythmias induced by reduction of transmission in
the atrioventricular node: ﬁrst-degree heart block in two
patients needing daily dose reduction, second- and third-
degree heart block in two others patients needing verapamil
discontinuation. In a previous study on 108 CH patients
using a mean daily dose of 584 ± 264 mg, incidence of
arrhythmia (mostly ﬁrst-degree heart block and junctional
rhythm) was 19% and bradycardia 36% [9]. In this study,
patients with arrhythmia (567 ± 290 mg/day) were not
taking higher doses than those without arrhythmia
(586 ± mg/day) [9]. By contrast, we found that patients
with EKG changes (1,003 ± 295 mg/day) were taking
higher doses than those without EKG changes (800 ±
143 mg/day), but doses were similar in patients with car-
diac SAE (990 ± 316 mg/day) and those with cardiac
Table 1 Cardiac safety of the very high verapamil CH patients
Sex Age TU CVH CH vD vSMD SM ACT PCT EKG changes SAE vC CAE
1 M 50 Present No C 108 96 1,200 scS No No No
2 M 21 No No E 84 72 960 scS No Second degree HB Yes Stop No
3 M 45 Present No E 12 2 960 scS No Bradycardia No No No
4 M 47 Present No C 72 60 840 scS T Bradycardia No No No
5 M 55 Past HBP E 1 1 720 scS No No D
6 M 34 Present No C 12 1 720 scS No No No
7 M 50 Present No C 36 24 1,440 scC No Bradycardia No No L
8 M 33 Present No E 48 1 720 scC No No No
9 M 46 Past No E 1 1 720 scC No No L
10 M 37 Present No E 1 1 720 scC No No C
11 M 72 Present No E 3 2.5 960 O2 No No C
12 M 51 Past No C 36 24 1,440 oZ No Third degree HB Yes Stop L–D
13 M 49 Present No C 120 96 960 scC L No No
14 M 52 Present No E 1 1 840 scC No First HB Yes ;600 D–E
15 M 30 No No E 1 1 960 No No Bradycardia No No No
16 M 33 Present No C 25 24 720 scS T-I Bradycardia No No L
17 M 37 Present HBP C 72 71 720 scC G First HB Yes ;840 No
18 M 40 Present No C 47 46 960 scC No No L–E
19 M 53 Past HBP C 96 93 720 scC No No L–D–I
20 M 37 Present No C 76 53 720 scC-O2 No No L–D–E
21 M 42 Present No C 17 10 720 scC I No L–E–G
22 W 34 Past No C 18 10 720 scC-O2 No No L
23 M 55 Present No C 53 51 720 scC No No L
24 M 41 Present No C 84 58 960 scC No No L–D–E
25 M 28 Present No C 37 36 720 scC-O2 No Bradycardia No No L
26 M 31 Present No C 81 46 720 scC I No No
27 M 52 Present No C 27 24 1,440 scC I Bradycardia No ;1,200 No
28 H 54 Past CAD C 71 53 720 scC No No No
29 H 33 Present No C 96 85 720 scC No No L
Sex, age (years), tobacco use (TU), cardiovascular history (CVH) with high blood pressure (HBP) and coronary arteries disease (CAD), type of
CH (E: episodic CH–C: chronic CH), duration of verapamil use (vD) in months, duration of supra-maximum dose of verapamil (vSMD) in
months, supra-maximum dose of verapamil achieved (SM) in mg/day, acute concomitant treatments (ACT/scC: subcutaneous sumatriptan–oZ:
oral –O2: oxygen), prophylactic concomitant treatments (PCT/I: indomethacin–G: gabapentin–L: lithium–T: topiramate), electrocardiogram
(EKG) changes, serious adverse event (SAE), change in verapamil dose (vC), clinical adverse events (CAE/C: constipation–D: dyspnea–E:
edema of lower limbs–G: gingival hyperplasia–I: impotence–L: lethargy)
Patients with serious cardiac adverse event are in bold and patient with nonserious cardiac adverse event are in italics
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123NSAE (1,011 ± 309 mg/day). In our study, cardiac
adverse events were not related to the patients’ age, car-
diovascular history, CH type and concomitant drugs used
for acute and/or prophylactic treatment of CH. All these
data are congruent with those previously reported [9] and
could be related to an interindividual variability in the
pharmacology of verapamil supported by a genetic com-
ponent [7]. This hypothesis was developed in the cardio-
logic ﬁeld and data collected in the INVEST suggests
variability in the large-conductance and voltage-dependant
potassium channel beta 1 subunit gene, KCNMB1, is
associated with the antihypertensive response to verapamil
and also with cardiovascular adverse events in patients
having hypertension with coronary arteries disease [12].
Our study also suggests an important intra-individual var-
iability in the risk of cardiac adverse events. Such an intra-
individual variability could explain the delayed onset of
cardiac adverse events which is probably the more striking
data collected in our study. Late-onset arrhythmia was
previously described in two CH patient treated with
verapamil [9]. Around three-quarters (8/11) of our patients
presented cardiac adverse events with a delayed onset, this
proportion being similar to bradycardia (5/7) and arrhyth-
mia (3/4). In all these late-onset adverse events cases, the
time between the adverse event occurrence date and that
corresponding to the very high daily dose verapamil use
was equal or higher than 2 years. This conﬁrms the need of
regular and systematic EKG monitoring as EKG abnor-
malities can develop insidiously with rising subthreshold
PR intervals, or suddenly after long time of normal EKGs.
This systematic assessment is all the more important than
cardiac adverse events can occur without any other clinical
adverse event as in four of our eight cases with late-onset
cardiac adverse event.
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